Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH, Dominik PK, Stanfield J, Ding S, Yang W, Kurd N, Llewellyn R, Heyen J, Wang C, Melton Z, Van Blarcom T, Lindquist KC, Chaparro-Riggers J, Salek-Ardakani S.
Chen SH, et al. Among authors: stanfield j.
J Immunother Cancer. 2021 Oct;9(10):e003464. doi: 10.1136/jitc-2021-003464.
J Immunother Cancer. 2021.
PMID: 34599020
Free PMC article.